The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
Open accessAbstract
Despite optimal treatment, including renin-angiotensin system (RAS) inhibitors, patients with type 2 diabetic nephropathy have high cardiorenal morbidity and mortality related to residual albuminuria. We evaluated whether or not atrasentan, a selective endothelin A receptor antagonist, further reduces albuminuria when administered concomitantly with maximum tolerated labeled doses of RAS inhibitors. We enrolled 211 patients with type 2 diabetes, urine albumin/creatinine ratios of 300-3500 mg/g, and eGFRs of 30-75 ml/min per 1.73 m(2) in two identically designed, parallel, multinational, double-blind studies. Participants were randomized to placebo (n=50) or to 0.75 mg/d (n=78) or 1.25 mg/d (n=83) atrasentan for 12 weeks. Compared with placebo, 0.75 mg and 1.25 mg atrasentan reduced urine albumin/creatinine ratios by an average of 35% and 38% (95% confidence intervals of 24 to 45 and 28 to 47, respectively) and reduced albuminuria≥30% in 51% and 55% of participants, respectively. eGFR and office BP measurements did not change, whereas 24-hour systolic and diastolic BP, LDL cholesterol, and triglyceride levels decreased significantly in both treatment groups. Use of atrasentan was associated with a significant increase in weight and a reduction in hemoglobin, but rates of peripheral edema, heart failure, or other side effects did not differ between groups. However, more patients treated with 1.25 mg/d atrasentan discontinued due to adverse events. After stopping atrasentan for 30 days, measured parameters returned to pretreatment levels. In conclusion, atrasentan reduced albuminuria and improved BP and lipid spectrum with manageable fluid overload-related adverse events in patients with type 2 diabetic nephropathy receiving RAS inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Self-citationFattinger, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114667 · Cited by 509
Avosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S. J., Littke, T., & Viberti, G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 492
Self-citationAtkins, R. C., Briganti, E. M., Lewis, J. B., Hunsicker, L. G., Braden, G., Champion de Crespigny, P. J., DeFerrari, G., Drury, P., Locatelli, F., Wiegmann, T. B., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.10.019 · Cited by 367
Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease
Schmieder, R. E., Mann, J. F. E., Schumacher, H., Gao, P., Mancia, G., Weber, M. A., McQueen, M., Koon, T., & Yusuf, S. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010091001 · Cited by 270
Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria
Wenzel, R. A. A. R., Littke, T., Kuranoff, S., Ju[Combining Diaeresis]rgens, C., Bruck, H., Ritz, E., Philipp, T., & Mitchell, A. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008050482 · Cited by 246
Kohan, D. E., Pritchett, Y., Molitch, M., Wen, S., Garimella, T., Audhya, P., & Andress, D. L. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080869 · Cited by 236
Self-citationOpgenorth, T. J., Adler, A. L., Calzadilla, S. V., Chiou, W. J., Dayton, B. D., Dixon, D. B., Gehrke, L. J., Hernandez, L., Magnuson, S. R., Marsh, K. C., et al. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12297-0 · Cited by 211
Dhaun, N., MacIntyre, I. M., Kerr, D., Melville, V., Johnston, N. R., Haughie, S., Goddard, J., & Webb, D. J. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.167486 · Cited by 160
Proteinuria should be used as a surrogate in CKD
Cravedi, P., Ruggenenti, P. L., & Remuzzi, G. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.42 · Cited by 157
Self-citationEndothelin, hypertension and chronic kidney disease: new insights
Kohan, D. E. (2010) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328335f91f · Cited by 126
Self-citationGagliardini, E., Corna, D., Zoja, C., Sangalli, F., Carrara, F., Rossi, M. G. D., Conti, S., Rottoli, D., Longaretti, L., Remuzzi, A., et al. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00340.2009 · Cited by 124
Self-citationEndothelin antagonists for diabetic and non‐diabetic chronic kidney disease
Kohan, D. E., & Pollock, D. M. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12064 · Cited by 122
Self-citationThe Kidney in Type 2 Diabetes Therapy
Heerspink, H. J. L., & de Zeeuw, D. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.392 · Cited by 79
Liver toxicity of sitaxentan in pulmonary arterial hypertension
Galiè, N., Hoeper, M. M., Gibbs, J. S. R., & Simonneau, G. (2011) · European Respiratory Journal · doi:10.1183/09031936.00194810 · Cited by 76
Simonson, M. S., & Ismail‐Beigi, F. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.190793 · Cited by 71
Ibsen, H., Olsen, M. H., Wachtell, K., Borch‐Johnsen, K., Lindholm, L. H., & Mogensen, C. E. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.4.566 · Cited by 41
Research works printed but not linked: 1
- de Zeeuw, 1995, Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome., J Hypertens Suppl, 13, S53, 10.1097/00004872-199507001-00008 · doi:10.1097/00004872-199507001-00008
Cited by
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
“116 In line with these hemodynamic observations, long-term treatment with endothelin-A receptor antagonists reduced residual albuminuria by 35% – 50% and seemingly preserved renal function in patients with T2DM that were optimally treated for their DKD. 117,118 As the anti-proteinuric effect of this drug class is alre…”
InfluentialSelf-citationDavenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Self-citationHeerspink, H. J. L., Parving, H.-H., Andress, D. L., Bakris, G., Correa-Rotter, R., Hou, F.-F., Kitzman, D. W., Kohan, D., Makino, H., McMurray, J. J. V., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30772-x · Cited by 628
Self-citation
Metadata
- Authors
- de Zeeuw, D., Coll, B., Andress, D., Brennan, J. J., Tang, H., Houser, M., Correa-Rotter, R., Kohan, D., Lambers Heerspink, H. J., Makino, H., Perkovic, V., Pritchett, Y., Remuzzi, G., Tobe, S. W., Toto, R., Viberti, G., & Parving, H.-H.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2014-05
- Volume
- 25
- Issue
- 5
- Pages
- 1083-1093
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2096179755
- Cited by
- 302
- References
- 17
- FWCI
- 22.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.